Biogen Idec BIIB and Swedish Orphan Biovitrum (Sobi) SOBI
today announced positive results from A-LONG, a clinical study that evaluated
a new long-lasting clotting factor candidate in people with hemophilia A.
Hemophilia A is a rare inherited disorder that impairs blood coagulation.
Top-line results from A-LONG, a global, multi-center, Phase 3 clinical study
of the companies' long-lasting recombinant Factor VIII Fc fusion protein
(rFVIIIFc), showed that rFVIIIFc was effective in the control and prevention
of bleeding, routine prophylaxis and perioperative management. Recombinant
FVIIIFc was generally well-tolerated. Additional analyses of the A-LONG study
are ongoing, and the companies anticipate presenting detailed results at a
future scientific meeting.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in